💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Grifols, S.A. (GRFS)
« Back to company indexGRFS Chatter Timeline
Stock Ticker for GRFS
Most Active Tweeters for GRFS
| User | Tweets |
|---|---|
| @newsfilterio | 5 |
| @TradeWithAlerts | 4 |
| @MarcJacksonLA | 3 |
| @SwingTradeBot | 2 |
| @EdgarInsider | 2 |
Recent Tweets for GRFS
 |
@NupeSauce I SEE YOU $GRFS April 19th 2021, 10:04pm |
 |
@SAFTHELABEL RT @NupeSauce: ? it’s time for $Grfs to blow! April 19th 2021, 8:04pm |
 |
@lilnickysmith $GRFS spike April 19th 2021, 4:04pm |
|
@NupeSauce ? it’s time for $Grfs to blow! April 19th 2021, 3:04am |
 |
@themechtutor @cdn_investing How about $GRFS. Grifols seems quite undervalued. April 17th 2021, 2:04pm |
 |
@newsfilterio Form 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC $GRFS https://t.co/Gy9RXlgDac April 17th 2021, 6:04am |
 |
@MarcJacksonLA $GRFS GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology https://t.co/VjmKutxAok April 16th 2021, 2:04pm |
 |
@EdgarInsider New Form 6-K entry filed by $GRFS #Grifols SA https://t.co/CuIHawRJDh April 16th 2021, 2:04pm |
|
@newsfilterio Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030 $GRFS https://t.co/dGQzyWKWtz April 16th 2021, 6:04am |
|
@newsfilterio GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology $GRFS https://t.co/fA4dn7QwIy April 15th 2021, 4:04pm |
 |
@otcdynamics $GRFS GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology https://t.co/liNyGL7faA April 15th 2021, 4:04pm |
 |
@FlashAlert_me $GRFS [15s. delayed]: Issued Press Release on April 15, 11:59:00: GigaGen Publishes Research on Company’s Recombina… https://t.co/QFozuY4dIj April 15th 2021, 4:04pm |
 |
@StckPro $GRFS NEW ARTICLE : Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030… https://t.co/ArIza08mzi April 15th 2021, 1:04pm |
 |
@SwingTradeBot 200 DMA Support today: $GRFS ... https://t.co/LjP7KUcNnp April 14th 2021, 2:04pm |
 |
@TradeWithAlerts Large Print $GRFS Size: 262186 Price: 17.83 Time: 934 Amount: $4,674,776.38 April 14th 2021, 1:04pm |
|
@TradeWithAlerts Large Print $GRFS Size: 250000 Price: 17.45 Time: 1504 Amount: $4,362,500.00 April 12th 2021, 7:04pm |
 |
@IrishInvestor This #Biotech does #Plasma Collection for Diseases, Medications & Viruses ? Like Covid $GRFS #thinkorswim https://t.co/NhF2tNNDki April 12th 2021, 6:04pm |
|
@SwingTradeBot 200 DMA Support today: $GRFS $VICR ... https://t.co/LjP7KUcNnp April 12th 2021, 2:04pm |
|
@TradeWithAlerts Large Print $GRFS Size: 129050 Price: 17.75 Time: 1037 Amount: $2,290,637.50 April 12th 2021, 2:04pm |
|
@newsfilterio Form 20-F (annual and transition report of foreign private issuers [sections 13 or 15(d)]) filed with the SEC $GRFS https://t.co/PvzzNa37Nh April 10th 2021, 6:04am |
|
@MarcJacksonLA $GRFS Grifols Files Annual Report https://t.co/LfDAuo2V0f April 9th 2021, 3:04pm |
|
@FlashAlert_me $GRFS [15s. delayed]: Issued Press Release on April 09, 10:30:00: Grifols 2020 Annual Report on Form 20-F filed wit… https://t.co/z6ufJIwdQe April 9th 2021, 2:04pm |
|
@newsfilterio Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 $GRFS https://t.co/IxFjhRBiPf April 9th 2021, 2:04pm |
 |
@stock_titan $GRFS Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 https://t.co/zBimf7ppuQ April 9th 2021, 2:04pm |
 |
@StockTexts $GRFS Grifols, S.A. SEC Filing: Form 20-F https://t.co/XWz4hB68Nb April 9th 2021, 1:04pm |
 |
@fintel_io $GRFS / Grifols files form 20-F https://t.co/zWdO0GXNEG April 9th 2021, 1:04pm |
 |
@M_Feratovic RT @RoyalOakInc: There has been much talk of elites using the blood of youth... Hmmm. $GRFS was mentioned April 8th 2021, 1:04pm |
 |
@RoyalOakInc There has been much talk of elites using the blood of youth... Hmmm. $GRFS was mentioned https://t.co/Ise52keXZD April 8th 2021, 1:04pm |
|
@MarcJacksonLA $GRFS Grifols Advances In Plan To Acquire 7 Plasma Centers In US ... https://t.co/69IJbIYiIU April 7th 2021, 2:04pm |
|
@TradeWithAlerts Large Print $GRFS Size: 120319 Price: 17.05 Time: 902 Amount: $2,051,438.95 April 7th 2021, 1:04pm |
|
@StockTexts $GRFS Grifols, S.A. SEC Filing: Form 6-K https://t.co/qOcKngGxgk April 7th 2021, 12:04pm |
|
@fintel_io $GRFS / Grifols files form 6-K https://t.co/zWdO0GXNEG April 7th 2021, 12:04pm |
|
@EdgarInsider Filing for 6-K has been made with the SEC: $GRFS #Grifols SA https://t.co/ze7iSPCksK April 7th 2021, 12:04pm |
 |
@Gambiste1 RT @OpenOutcrier: $GRFS (-0.5% pre) Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globu… April 6th 2021, 10:04am |
|
@SwingTradeBot Rose Above 50 DMA today: $GRFS ... https://t.co/qwiJH6vr1O April 5th 2021, 4:04pm |
|
@MarcJacksonLA $GRFS Grifols’ combination treatment fails to meet endpoints in Covid-19 study https://t.co/6ROFGcRKUk via @Clinical Trials Arena April 5th 2021, 3:04pm |
 |
@OpenOutcrier $GRFS (-0.5% pre) Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune… https://t.co/KAGHQC73BH April 5th 2021, 11:04am |
 |
@Briefingcom $GRFS: Grifols, S.A. reports topline data from NIAID Phase 3 ITAC trial did not meet primary endpoint https://t.co/IutuvUtseZ April 5th 2021, 11:04am |
|
@MarcJacksonLA $GRFS Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins a… https://t.co/RISqIYG0w7 April 3rd 2021, 2:04pm |
|
@NupeSauce $GRFS I dodged the dip. Keep dropping babyyyy April 3rd 2021, 12:04pm |
 |
@BertrandBio RT @BioStocks: $GRFS Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with #COVID… April 2nd 2021, 4:04pm |
 |
@BioStocks $GRFS Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients wi… https://t.co/AZaCYhSMBs April 2nd 2021, 4:04pm |
 |
@sbwcws Grifols Phase 3 study in hospitalized Covid patients did not meet endpoints $GRFS April 2nd 2021, 3:04pm |
|
@SwingTradeBot Recent $GRFS technical alerts: Expansion Pivot Sell Setup plus 9 more alerts... https://t.co/F1c5WU78fW April 2nd 2021, 3:04pm |
|
@FlashAlert_me $GRFS [15s. delayed]: Issued Press Release on April 02, 11:18:00: Grifols announces topline data from NIAID Phase 3… https://t.co/GUBfb3qkJh April 2nd 2021, 3:04pm |
 |
@Beeken_health $GRFS - Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins… https://t.co/tM8UFdTauS April 2nd 2021, 3:04pm |
|
@StckPro $GRFS NEW ARTICLE : Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmu… https://t.co/TT98sHoMzJ April 2nd 2021, 3:04pm |
|
@stock_titan $GIKLY $GRFS Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune glob… https://t.co/HgHVqu9F2n April 2nd 2021, 3:04pm |
|
@NupeSauce $GRFS $20 by 2021? March 31st 2021, 4:03pm |
|
@MarcJacksonLA $GRFS Grifols Upgraded to Outperform at Credit Suisse Group | https://t.co/NKb5pRLCDo https://t.co/Xzf9FVZn2Z March 29th 2021, 3:03pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
➤ Free Trial
